Corixa is a developer of immunotherapeutics with a commitment to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system. Having founded in 1994, the company conducted various preclinical development programs, including the BEXXAR® therapy and the MELACINE® vaccine. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a standalone basis. The company partners with numerous developers and marketers of pharmaceuticals, targeting products that are powered by Corixa™ technology with the goal of making its potential products available to patients around the world. Corixa was acquired by GlaxoSmithKline on 12 July 2005, and GSK had formerly made use of the Corixa's MPL adjuvant in some of their vaccines. The company ceased operations in March 2006.

mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec® Histology kit and CINtec® Cytology kit as adjunct tools for the early detection and diagnosis of cervical cancer.\nThese kits are based on mtm's proprietary E6H4™ antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results.\nmtm laboratories AG also has programs to identify and develop biomarker based diagnostics for other cancer indications. With its extensive and ever increasing network of clinical research institutions, academic research organizations, and medical professionals active in the field of oncology and molecular pathology, mtm has established a rapid, integrated process for the successful identification and clinical validation of molecular markers associated with cancer.

Regents of The University of Michigan provides administers bonds on behalf of the University. The company is headquartered in Ann Arbor, MI.

Ventana Medical Systems, Inc., is a world leader and innovator of tissue-based diagnostic solutions for patients worldwide. The company passionately pursues its mission to improve the lives of all patients afflicted with cancer. Ventana Medical Systems discover, develop, and deliver medical diagnostic systems and biopsy based cancer tests that are shaping the future of healthcare. As the leading supplier of cancer diagnostic systems to the pathology market, Ventana manufactures over 220 cancer tests with related instruments right here in southern Arizona for 80 countries, and most importantly, for 4 million people afflicted with cancer yearly around the world. Ventana products provide healthcare professionals with a total solution for all critical steps involved in the analysis of tissue biopsies. This pioneering company also offers premier workflow solutions to improve laboratory efficiency and preserve patient safety. Ventana is committed to accelerating the discovery and development of new cancer tests that allow pathologists to analyze patient samples at the molecular level to help determine the best course of therapy for each individual patient. Ventana enables this with its global leadership as the number one Pharma Industry Partner of Choice in the development and commercialization of companion diagnostics for cancer patients. Ventana Medical Systems is a member of the Roche Group that is drawing on powerful partnerships with world-class scientific institutions.

In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. At Takeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer. They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.

Alcyone Lifesciences develops a platform of technology that optimizes molecular therapy for the brain. It addresses the unmet needs in the treatment of chronic neuropathological conditions. For many neurologic conditions, there are identified molecular targets, but the blood-brain barrier prevents drugs from addressing those targets from reaching diseased brain regions in a controlled and targeted manner. In addition, there is a fundamental need for control and precision in molecular therapy to the CNS. The company is transforming disease-modifying therapies for rare and orphan disorders through Advanced Precision Delivery Platforms.

Light Sciences Corp. was manufactured biopharmaceuticals and biotherapeutics products. The company was founded in 1995 and was headquartered in Snoqualmie, WA.

OncoPlexDx is a CLIA-certified cancer diagnostics laboratory in Rockville, MD that provides clinical proteomics for patient care. By quantitating proteins, It provide information that helps physicians choose targeted therapies and avoid therapies that won’t work.

Lisen Imprinting Diagnostic Technology (Wuxi) Co., Ltd., established on 2016-10-21, Business scope includes probes,Kit experimental material development;Diagnostic Technology R&D;Technology development in the field of biotechnology,technical consulting,Technical Services and Technology Transfer;Development of diagnostic reagents;biological reagent,Sales of Class I Medical Devices;Production of Class I Medical Devices.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Electrophoretics Ltd., a subsidiary of Proteome Sciences Plc, is a British company located in London. The firm engages in research and experimental development on natural sciences. It was founded in 1992.

Light Sciences Oncology develops cancer and tumor treatment drugs. Additionally, it offers oncology drugs research and development services to treat hepatocellular carcinoma, metastatic colorectal cancer, and glioma. Light Sciences Oncology was founded in 1994 and is headquartered in Bellevue, Washington.

Shanghai Pulmonary Hospital, a subsidiary of Tongji University, is a Chinese company located in Shanghai that provides medical services.

Exact Sciences is a molecular diagnostics company focused on colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA (sDNA) technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer.

Hangzhou Dixiang Industrial Co., Ltd., established on 2015-01-08, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;New material technology research and development;Biochemical product technology research and development;Research and development of bio-based materials technology;Research and development of bio-based material polymerization technology;Smart Home Gateway Manufacturing;Artificial intelligence application software development;software development;Natural science research and experimental development;Engineering and Technology Research and Experimental Development;Specialty Chemicals Sales(Free of Hazardous Chemicals);Sales of bio-based materials;Sales of Class I Medical Devices;IoT Device Sales;business management;Corporate Headquarters Management;Holding Company Services;Technology Import and Export;Import and export;Industrial Investment(Not approved by financial and other regulatory authorities,Not engage in financing deposits with the public,financing guarantee,Financial services such as wealth management on behalf of customers)(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).

NeRRe Therapeutics Ltd. provides clinical and pre clinical drugs for treatment of neuronal hypersensitivity. It develops neurokinin receptor antagonists acquired from GlaxoSmithKline. The company was founded by Emiliangelo Ratti and Mike Trower in 2012 and is headquartered in Stevenage, the United Kingdom.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Ramot at Tel Aviv University Ltd. operates as a technology transfer company of Tel Aviv University (TAU). It provides legal and commercial frameworks for inventions made by TAU faculty, students, and researchers. The firm licenses the university's intellectual property to third parties through agreements; facilitates collaborative research partnerships between business partners and TAU researchers; establishes a company; and forms joint ventures that promote TAU technologies. The company was founded in 1973 and is headquartered in Tel Aviv, Israel.

Beijing Cornerstone Life Technology Co., Ltd., established on 2016-06-20, Business scope includes technical services,Technology Promotion;Conference Services;computer technology training(Cannot be recruited nationwide);software development,computer repair;Computer System Services;Economic and Trade Consulting;Sales of chemical products(Does not contain dangerous chemicals and a class of precursor chemicals),electronic product,Equipment,computer,Software and Auxiliary Equipment;Natural science research and experimental development;Engineering and Technology Research and Experimental Development;Medical Research and Experimental Development;Import and export,Agent import and export,Technology Import and Export;Technical testing.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)